HomeALIM • NASDAQ
Follow
Alimera Sciences Inc
Previous close
$3.90
Day range
$3.76 - $4.01
Year range
$1.56 - $4.38
Market cap
204.18M USD
Avg Volume
86.09K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 26.31M | 87.51% |
Operating expense | 21.96M | 56.69% |
Net income | -3.78M | -0.03% |
Net profit margin | -14.37 | 46.66% |
Earnings per share | -0.07 | 87.71% |
EBITDA | 3.76M | 364.14% |
Effective tax rate | -0.19% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 12.06M | 128.63% |
Total assets | 153.52M | 260.37% |
Total liabilities | 107.35M | 69.30% |
Total equity | 46.17M | — |
Shares outstanding | 52.35M | — |
Price to book | 4.43 | — |
Return on assets | 1.18% | — |
Return on capital | 1.58% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -3.78M | -0.03% |
Cash from operations | 3.77M | 1,601.99% |
Cash from investing | -85.00K | -1.19% |
Cash from financing | -78.00K | 59.59% |
Net change in cash | 3.77M | 1,685.71% |
Free cash flow | 5.45M | 1,286.46% |
About
Alimera Sciences, Inc. is a biopharmaceutical sales company based in Alpharetta, Georgia that specializes in the commercialization and sales of prescription ophthalmic pharmaceuticals. The company's main selling focus is on diseases affecting the back of the eye, or retina. The company is the licensee for Iluvien, a fluocinolone acetonide intravitreal implant. Wikipedia
Founded
2003
Headquarters
Website
Employees
157